腾盛博药-B(02137.HK) 公布，有意根据股东于今年6月25日通过的决议案，授予董事的一般授权行使其权力，以购回不超过于今年6月25日的已发行股份总数10%的腾盛博药股份。
考虑到公司股价现时处于业绩、资产价值及业务前景被低估的水平，董事会于今日(20日)决议动用购回授权，不时因应市况于公开市场积极推行场内股份购回计划。据该股份购回计划，用于购回股份的资金总额不超过6,000万元，股份购回计划的期限自今日起至公司于2025年举行下届股东周年大会之日止。
另外，腾盛博药董事会主席Zhi Hong已于较早前获董事会批准，购入不超过200万股股份。截至今日，Zhi Hong已购入49.95万股股份。(js/u)
(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.